L26/O-201 Should we modify ovarian stimulation? Within-patient modifications and their impact on oocyte yield in subsequent cryopreservation cycles: a retrospective cohort study
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.199 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von D. Lasry und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Within the same patient undergoing planned oocyte cryopreservation, do stimulation modifications (protocol, medications, dosage, or trigger type) result in clinically meaningful changes in oocyte yield? Summary answer Across consecutive cycles, modifying medication, dosage, or trigger was not associated with clinically meaningful differences in total or mature oocyte yield. What is known already Planned oocyte cryopreservation (POC) is increasingly universally utilized, with many women undergoing multiple stimulation cycles to maximize the total number of banked oocytes. In clinical practice, stimulation protocols, gonadotropin regimens, dosing, and trigger strategies are frequently modified after in the following cycle in an attempt to improveoutcome. interpretation of cycle-to-cycle differences is complicated, however, by natural inter-cycle biological variability and changes in follicular cohort recruitment within the same patient. While within-patient comparisons reduce inter-individual confounding, data evaluating whether treatment modifications meaningfully influence oocyte yield across consecutive cycles remain limited. Study design, size, duration This retrospective cohort study was conducted at a single university-affiliated medical center. Women undergoing POC between January 2018 and 2025 were eligible if they completed two consecutive stimulation cycles for oocyte cryopreservation within one-year. For each participant, only the first and second cycles were included. Clinical, laboratory, and treatment data were retrospectively extracted from electronic medical records. Participants/materials, setting, methods The study included women undergoing POC. Data collected included demographic characteristics and treatment variables, including stimulation protocol (Antagonist versus other), gonadotropin medication, starting dose, and trigger type. Change in any of these parameters was defined as a treatment modification. Primary outcomes were cycle-to-cycle differences in total and mature oocyte (MII) yield difference, analysed according to the presence and number of treatment modifications. The differences were calculated by subtracting the second cycle outcome from the first. Main results and the role of chance The study included 333 women aged 30–40 years (mean 34.5 ± 3.3). Mean FSH was 7.5 ± 3.2 IU/L, AMH 2.2 ± 3.8 ng/mL, and AFC 12.8 ± 8.6. Diminished ovarian reserve (DOR) was present in 27.9% of participants. Median BMI was 23.5 kg/m². Protocol modification between consecutive cycles was rare, whereas other changes were common. In the second cycle, protocol, trigger, medication, and dose were modified in 2.7%, 21.9%, 16.2%, and 58.0% of women, respectively. Since protocol changes were infrequent, the analysis focused only on cycles with unchanged antagonist protocols (n = 324). Among women with no protocol change: 27.8% had no additional modifications, 53.4% had one, 15.4% had two, and 3.4% had three modifications. Changes in trigger, dose, or medication were not associated with total oocyte difference (p = 0.68, p = 0.16, and p = 0.96, respectively), or mature oocyte difference (p = 0.60, p = 0.37 and p = 0.42, respectively). Mean differences in total oocyte yield were small across modification categories: 0 changes: +0.4 ± 4.8; 1 change: +0.7 ± 5.0; 2 changes: +0.7 ± 4.6; 3 changes: +1.6 ± 2.7[DL1]. Similar findings were observed in women with DOR (n = 93), with no significant differences in total or MII oocyte yield following consecutive modifications. Limitations, reasons for caution The retrospective, single-center design limits generalizability. Treatment modifications reflected routine clinical decision-making rather than randomization. In addition, natural cycle-to-cycle variability in follicular cohort recruitment within the same patient may influence outcomes independent of protocol changes, and results may be affected by center-specific laboratory practices. Wider implications of the findings To our knowledge, this is the first study to evaluate the impact of combined multiple stimulation modifications within the same patient undergoing consecutive oocyte cryopreservation. Changes in dose, medication, or trigger were not associated with change in oocyte yield. These data may help clinicians avoid unnecessary protocol changes. Trial registration number No
Zitieren
APA
Lasry, D., Tov, Y. B., Mostafa, J., Hizkiyau, R., Godin, M., Broder, E. E., Lazarovits, C. A., Gilad, M. K., & Klement, A. H. (2026). L26/O-201 Should we modify ovarian stimulation? Within-patient modifications and their impact on oocyte yield in subsequent cryopreservation cycles: a retrospective cohort study. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.199
Vancouver
Lasry D, Tov YB, Mostafa J, Hizkiyau R, Godin M, Broder EE, et al. L26/O-201 Should we modify ovarian stimulation? Within-patient modifications and their impact on oocyte yield in subsequent cryopreservation cycles: a retrospective cohort study. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.199
BibTeX
@article{Lasry2026,
author = {Lasry, D. and Tov, Y. Ben and Mostafa, J. and Hizkiyau, R. and Godin, M. and Broder, E. Esh and Lazarovits, C. Adler and Gilad, M. Ketzinel and Klement, A. Hershko},
title = {L26/O-201 Should we modify ovarian stimulation? Within-patient modifications and their impact on oocyte yield in subsequent cryopreservation cycles: a retrospective cohort study},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.199}
}
EUVIMED